Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline
Biogen Inc. (NASDAQ:BIIB) announced Tuesday that its investigational therapy diranersen slowed clinical decline at two years in people living with early Alzheimer’s disease, according to new Phase 2 CELIA study data. Presenters shared the Week 96 findings at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference. The results showed that diranersen, an antisense oligonucleotide (ASO)…
We haven't written up this one. Benzinga has the full story — the link below goes straight to it.